Education
About Us
Working with TipRanks
Follow Us
PTC Therapeutics (PTCT)
:PTCT
PTCT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$34.57 - $63.19
Previous CloseN/A
Volume146.45K
Average Volume (3M)1.34M
Market Cap
$4.69B
Enterprise Value$2.22B
Total Cash (Recent Filing)$1.99B
Total Debt (Recent Filing)$388.17M
Price to Earnings (P/E)8.5
Beta1.25
Next Earnings
Oct 23, 2025EPS Estimate
-1.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.83
Shares Outstanding79,438,095
10 Day Avg. Volume1,347,453
30 Day Avg. Volume1,344,890
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.47
Enterprise Value/Revenue1.26
Enterprise Value/Gross Profit1.26
Enterprise Value/Ebitda2.64
Forecast
1Y Price Target
$65.40Price Target Upside10.87% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering17
Bulls Say, Bears Say
Bulls Say
Market OpportunityPTCT anticipates the ex-US opportunity will be a significant contribution to future revenues.
Sephience LaunchAnalyst maintains a positive outlook for the Sephience launch in PKU following the approval end of July.
Stock OutlookThere is a positive outlook for PTCT stock over the coming months, with focus shifting to PKU launch dynamics and potential updates for PTC518.
Bears Say
Clinical Trial ResultsThe placebo-controlled portion of the phase 3 trial failed to demonstrate a statistically significant benefit on the mFARS primary endpoint.
Regulatory ChallengesPTCT announced this morning that they have received a complete response letter (CRL) from the FDA for vatiquinone in Friedreich's ataxia (FA).
PTC Therapeutics News
PTCT FAQ
What was PTC Therapeutics’s price range in the past 12 months?
PTC Therapeutics lowest stock price was $34.57 and its highest was $63.19 in the past 12 months.
What is PTC Therapeutics’s market cap?
PTC Therapeutics’s market cap is $4.69B.
When is PTC Therapeutics’s upcoming earnings report date?
PTC Therapeutics’s upcoming earnings report date is Oct 23, 2025 which is in 25 days.
How were PTC Therapeutics’s earnings last quarter?
PTC Therapeutics released its earnings results on Aug 07, 2025. The company reported -$0.83 earnings per share for the quarter, beating the consensus estimate of -$1.021 by $0.191.
Is PTC Therapeutics overvalued?
According to Wall Street analysts PTC Therapeutics’s price is currently Undervalued.
Does PTC Therapeutics pay dividends?
PTC Therapeutics does not currently pay dividends.
What is PTC Therapeutics’s EPS estimate?
PTC Therapeutics’s EPS estimate is -1.02.
How many shares outstanding does PTC Therapeutics have?
PTC Therapeutics has 79,438,095 shares outstanding.
What happened to PTC Therapeutics’s price movement after its last earnings report?
PTC Therapeutics reported an EPS of -$0.83 in its last earnings report, beating expectations of -$1.021. Following the earnings report the stock price went down -9.889%.
Which hedge fund is a major shareholder of PTC Therapeutics?
Currently, no hedge funds are holding shares in PTCT
PTC Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$65.40 (10.87% Upside)
$65.40 (10.87% Upside)
Blogger Sentiment
Bullish
PTCT Sentiment 70%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 345.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.3%
Last 30 Days ▼ 1.7%
Last 30 Days ▼ 1.7%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
56.63%
12-Months-Change
Fundamentals
Return on Equity
33.08%
Trailing 12-Months
Asset Growth
37.46%
Trailing 12-Months
Company Description
PTC Therapeutics
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
PTCT Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements, including the approval and launch of Sephience in major markets and a strong financial position. However, challenges were noted with Translarna and Emflaza revenues. Overall, the sentiment was positive, with promising growth prospects for Sephience.View all PTCT earnings summariesPTCT Stock 12 Month Forecast
Average Price Target
$65.40
▲(10.87% Upside)
Technical Analysis
Ownership Overview
1.38% Insiders
26.86% Mutual Funds
26.66% Other Institutional Investors
26.02% Public Companies and
Individual Investors